ASCO 2018 | Promising new therapies for multiple myeloma
In this interview, Faith Davies, MD, MRCP, MRCPath, FRCPath, from UAMS Myeloma Institute, Little Rock, AR, discusses the various drugs that are either approved or currently in trials for multiple myeloma (MM) treatment. In the relapsed setting, elotuzumab, revlimid and dexamethasone have already been approved; however, results are eagerly awaited for the upfront setting, as well as combination studies. She also highlights the use of daratumumab in several different combinations, with results suggesting it is reliable, versatile and comes with minimal side effects. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Get great new content delivered to your inboxSign up